1257044-40-8
- Product Name:Venetoclax
- Molecular Formula:C45H50ClN7O7S
- Purity:99%
- Molecular Weight:868.454
Product Details;
CasNo: 1257044-40-8
Molecular Formula: C45H50ClN7O7S
Factory Supply industrial standard Venetoclax 1257044-40-8 In Stock We supply high quality ABT-199 (CAS 1257044-40-8), in stock, factory directly supply to clients, lower prices, more competitiveness.
What is the ABT-199 ?
ABT-199 is , while it's Molecular Formula is C45H50ClN7O7S. ABT 199 (>99%) is a potent and selective BCL-2 inhibitor that achieves potent antitumour activity while sparing platelets. It’s practical application is to treat chronic lymphocytic leukaemic cells and estrogen receptor-positive breast cancer.
What is the CAS number for ABT-199 ?
The CAS number of ABT-199 is 1257044-40-8.
More information of ABT-199 1257044-40-8 are:
|
Synonyms |
Venetoclax |
|
CAS Number |
1257044-40-8 |
|
Molecular Formula |
C45H50ClN7O7S |
|
Molecular Weight |
868.454 |
|
Density |
1.340±0.06 g/cm3(Predicted) |
|
PSA |
183.09000 |
|
LogP |
10.73070 |
|
Pka |
4.09±0.10(Predicted) |
What is ABT-199 (1257044-40-8) used for?
Venetoclax, codeveloped by AbbVie (previously Abbott Laboratories) and Genentech/ Roche, was approved in the US for treatment of patients with chronic lymphocytic leukemia (CLL). To meet qualifications for venetoclax treatment, patients must have received prior therapy and possess the 17p deletion genetic mutation, as determined by USFDA testing. Venetoclax functions as a selective inhibitor of B cell lymphoma subtype 2 (BCL-2), which is often overexpressed on malignant cells and thus leads to impairment of the apoptotic pathway. Along these lines, the orally dosed small molecule drug restores the ability of malignant cells to undergo apoptosis as its mechanism of action.90 Although other BCL-2 inhibitors are known, development of similar agents such as navitoclox have been pursued and halted due to undesired inhibition of BCL-XL, leading to significant thrombocytopenia and demonstrating the need for more selective inhibitors. Venetoclax is also currently being considered for approval in Europe and Canada for similar indications and is in various stages of development for the treatment of non-Hodgkin lymphomas (NHL), acute myeloid leukemia (AML), multiple myeloma (MM), and several other disorders, either as a combination therapy or a stand-alone treatment.
Articles related to ABT-199:
|
Article |
Source |
|
A PROCESS FOR THE PREPARATION OF VENETOCLAX AND ITS POLYMORPHS THEREOF |
- , (2021/02/12) |
|
Preparation method of BCL-2 inhibitor venetoclax |
- Paragraph 0029; 0040-0041, (2020/03/23) |
How to get the best price on ABT-199?
Shandong Juntai Pharmaceutical Co., Ltd. is a quality supplier and manufacturer of ABT-199 . You can buy high quality, low price ABT-199 1257044-40-8 here. Contact us.
Relevant Products
-
EDC·HCL
CAS:25952-53-8
-
Elexacaftor
CAS:2216712-66-0
-
Semaglutide
CAS:910463-68-2



